2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1551 High efficacy of obe-cel and brexu-cel in patients with extramedullary B-ALL

Karamjeet Singh Sandhu, MD, Amy Zhang, MPH2, Vamsi Kota, MD3, Jacob Boccucci, MD4, Matthew L. Ulrickson, MD5, Jumana Hoque, MBBS6, LaQuisa Hill, MD7, Meera Khosla, MD8, Anjali Sunder Advani, MD9, John Carlos Molina, MD, MEd10, Tamer Othman, MD11, Mathew G. Angelos, MD, PhD12, Marlise Rachael Luskin, MD, MSCE13, Evan C. Chen, MD14, Chenyu Lin, MD15, Ryan D. Cassaday, MD16, Noam Kopmar, MD17, Brian McClune, DO18, Silvina Odstrcil Bobillo19, Stephanie B Tsai, MD20, Timothy Edward O'Connor, MD21, Talal Hilal, MD22, Partow Kebriaei, MD23, Nitin Jain, MD24, Elias Jabbour, MD25, Bijal Shah, MD, MS26, Rawan Faramand, MD27, Jae H Park, MD28, Yannis K. Valtis I, MD29, Melhem Solh, MD30, Caitlin Guzowski, MBA31, Jessica Leonard I, M.D.32, Virginia Tan, MD33, Sumithira Vasu, MBBS., MD34, Jiasheng Wang, MD35, Navneet Majhail, MD36, Minoo Battiwalla, MD37, Shahbaz Malik, MD38, Luke Mountjoy, DO39, Aravind Ramakrishnan, MD40, Paul Shaughnessy, MD41, Hrishikesh Srinagesh, MD, MSCR42, Katherine Sutherland, PA43, Muthu Kumaran, MD44, Caspian Oliai, MD45, Georgia Lill, MD46, Kaitlyn Cecilia Dykes, MD47, Aaron C. Logan, MD, PhD, MPhil48, George Yaghmour, MD49, Gregory W Roloff, MD50, Ken Byrd, DO51, Fevzi Yalniz, MD52, Veronika Bachanova, MD, PhD53, Sean I. Tracy, MD, PhD54, Noelle Frey, MD, MSCE55, Vivian Irizarry Gatell, MD56, Clayton Jackson, MD57, Olalekan Oluwole, MD, MPH58, Bhagirathbhai Dholaria, MD, FACP59, Lori Muffly, MD60, Ibrahim Aldoss, MD61
1 City of Hope, Duarte, California, United States
2 Stanford University School of Medicine, Palo Alto, California, United States
3 Augusta University, Atlanta, Georgia, United States
4 Augusta University, Atlanta, Georgia, United States
5 Banner MD Anderson Cancer Center, Phoenix, Arizona, United States
6 Banner MD Anderson Cancer Center, Phoenix, Arizona, United States
7 Baylor College of Medicine, Houston, Texas, United States
8 Baylor College of Medicine, Houston, Texas, United States
9 Cleveland Clinic, Cleveland, Ohio, United States
10 Cleveland Clinic, Cleveland, Ohio, United States
11 City of Hope, Duarte, California, United States
12 University of Colorado, Aurora, Colorado, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 Duke University School of Medicine, Durham, North Carolina, United States
16 Fred Hutchinson Cancer Center, Seattle, Washington, United States
17 Fred Hutchinson Cancer Center, Seattle, Washington, United States
18 University of Utah, Salt Lake City, Utah, United States
19 University of Utah, Salt Lake City, Utah, United States
20 Loyola University Medical Center, Maywood, Illinois, United States
21 Loyola University Medical Center, Maywood, Illinois, United States
22 Mayo Clinic, Phoenix, Arizona, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
26 Moffitt Cancer Center, Tampa, Florida, United States
27 Moffitt Cancer Center, Tampa, Florida, United States
28 Memorial Sloan Kettering Cancer Center, New York, New York, United States
29 Memorial Sloan Kettering Cancer Center, New York, New York, United States
30 Northside Hospital Cancer Institute, Atlanta, Georgia, United States
31 Northside Hospital Cancer Institute, Atlanta, Georgia, United States
32 Oregon Health & Science University, Portland, Oregon, United States
33 Oregon Health & Science University, Portland, Oregon, United States
34 The Ohio State University, Columbus, Ohio, United States
35 The Ohio State University, Columbus, Ohio, United States
36 Sarah Cannon Cancer Network, Nashville, Tennessee, United States
37 Sarah Cannon Cancer Network, Nashville, Tennessee, United States
38 Sarah Cannon Cancer Network at Texas Transplant Institute, Austin, Texas, United States
39 Sarah Cannon Cancer Network at Colorado Blood Cancer Institute, Denver, Colorado, United States
40 Sarah Cannon Transplant and Cellular Therapy Program at St. David's South Austin Medical Center, Austin, Texas, United States
41 Sarah Cannon Transplant and Cellular Therapy Program at Methodist Hospital, San Antonio, Texas, United States
42 Stanford University School of Medicine, Palo Alto, California, United States
43 Stanford University School of Medicine, Palo Alto, California, United States
44 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
45 University of California Los Angeles School of Medicine, Los Angeles, California, United States
46 University of California Los Angeles School of Medicine, Los Angeles, California, United States
47 University of California San Diego School of Medicine, La Jolla, California, United States
48 University of California San Francisco School of Medicine, San Francisco, California, United States
49 University of Southern California School of Medicine, Los Angeles, California, United States
50 University of Chicago School of Medicine, Chicago, Illinois, United States
51 The University of Kansas Cancer Center, Kansas City, Kansas, United States
52 University of Kentucky - Markey Cancer Center, Lexington, Kentucky, United States
53 University of Minnesota, Minneapolis, Minnesota, United States
54 University of Minnesota, Minneapolis, Minnesota, United States
55 University of Pennsylvania, Philadelphia, Pennsylvania, United States
56 University of Texas - Southwestern, Dallas, Texas, United States
57 University of Texas - Southwestern, Dallas, Texas, United States
58 Vanderbilt University Medical Center, Nashville, Tennessee, United States
59 Vanderbilt University Medical Center, Nashville, Tennessee, United States
60 Stanford University School of Medicine, Palo Alto, California, United States
61 City of Hope, Duarte, California, United States

Introduction: CD19-directed chimeric antigen receptor T cell therapy (CAR-T) has demonstrated remarkable efficacy in treating relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). Currently, obecabtagene autoleucel (Obe-cel) and brexucabtagene autoleucel (brexu-cel) are approved for adults with r/r B-ALL. Beyond high response rate and durable remission, CAR-T has shown promising activity against extramedullary disease (EMD), a clinical setting in which other therapies often have limited efficacy. While the antileukemic activity of CAR-T for central nervous system (CNS) disease has been described, less is known about its efficacy in non-CNS EMD.

Methods: This analysis utilized the ROCCA database, a multicenter registry that compiles real-world outcomes of adult patients (pts)with B-ALL treated with commercially approved CAR-T. Adults with r/r B-ALL and documented EMD involvement prior to apheresis who subsequently received either commercial obe-cel or brexu-cel between January 2023 and April 2026 were included. Data cutoff was June 25, 2026.  Pts with CNS involvement as the sole site of EMD were excluded. EMD was assessed at baseline and evaluated for response using imaging studies per institutional standards and local practice. Bone marrow (BM) measurable residual disease (MRD) was assessed by next generation sequencing and/or flow cytometry. American Society for Transplantation and Cellular Therapy (ASTCT) criteria were followed to characterize cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS). Clinical outcomes, including response of non-CNS EMD sites, MRD status, and survival endpoints, were analyzed following CAR-T cell infusion.

Results: A total of 116 pts with r/r B-ALL who received CAR-T for EMD present at apheresis were identified, including 28 received obe-cel and 88 received brexu-cel. The median follow up for the whole cohort was 12.4 months (5.5 months for obe-cel and 17.1 months for brexu-cel).

For the overall cohort, the median age at infusion was 37 (30-55) years, 39% had high-risk cytogenetics or molecular features, and the median number of prior therapy lines was 3 (2-5). Prior blinatumomab exposure and allogeneic stem cell transplant (alloHCT) were reported in 70 (60%) and 52 (45%) pts, respectively. In addition to active EMD, BM involvement was present in 62 (53%) pts at apheresis and 29 (25%) pre-infusion. The most common sites of EMD were lymphatic 34 (29%), bone 32 (28%), and skin 15 (13%). EMD was reassessed prior to lymphodepletion (LD) in 56 (48%), of which most 45 (80%) had persistent EMD.

Baseline characteristics were generally comparable between the obe-cel and brexu-cel cohorts. However, pts receiving brexu-cel (relative to obe-cel) were more likely to have active EMD plus BM disease at apheresis (65% vs. 18%) and less likely to receive bridging therapy (78% vs. 96%). Most obe-cel pts (n=20; 71%) had documented ongoing EMD pre-LD; EMD was not reassessed in the majority of brexu-cel pts (n=57; 65%) pre-LD.

Any-grade and grade ≥3 CRS occurred in 64% and 0% of obe-cel pts, compared with 85% and 11% of brexu-cel pts, respectively. Any-grade and grade ≥3 ICANS occurred in 19% and 4% of obe-cel pts versus 44% and 22% of brexu-cel pts, respectively.

Among evaluable pts in the overall cohort, the CR/CRi rate after CAR-T was 95% and the undetectable MRD rate was 85%. CR/CRi and undetectable MRD rates were 100% and 86% among obe-cel recipients, compared with 93% and 85% among brexu-cel recipients.

Post obe-cel and brexu-cel therapy, 14% and 34% of pts underwent alloHCT consolidation, respectively. Six-month EFS and OS were 62% and 83% for the entire cohort; outcomes were not significantly different after obe-cel and brexu-cel, as measured by EFS (57% vs. 63%, p = 0.47) and OS (73% vs. 85%, p = 0.19), respectively. Six-month cumulative incidence of relapse was 26% for obe-cel and 20% for brexu-cel (p=0.39).

Conclusions: In this relatively large cohort of adults with R/R B-ALL with active EMD, a particularly challenging population with limited therapeutic options, CAR-T demonstrated noteworthy efficacy. Response rates were high. Survival outcomes were comparable between the two FDA-approved CD19 targeting products, though longer follow-up time is needed. These findings support the effectiveness of CAR-T in treating EMD and reinforce its role as a key treatment strategy in this challenging clinical setting.

Karamjeet Singh Sandhu, MD: Autolus - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)